Related references
Note: Only part of the references are listed.The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study
Benjamin M. Scirica et al.
AMERICAN HEART JOURNAL (2011)
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects
Vijay V. Upreti et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
David W. Boulton et al.
CLINICAL PHARMACOKINETICS (2011)
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus
Jean Doucet et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
Matteo Monami et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
Antonio R. Chacra et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
Priscilla L. Hollander et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
C. F. Deacon
DIABETES OBESITY & METABOLISM (2011)
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
A. Pfuetzner et al.
DIABETES OBESITY & METABOLISM (2011)
Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects
C. G. Patel et al.
DIABETES OBESITY & METABOLISM (2011)
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
M. Nowicki et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial
Wenying Yang et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Linagliptin In Type 2 Diabetes Mellitus
Lesley J. Scott
DRUGS (2011)
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors Similarities and Differences
Roberta Baetta et al.
DRUGS (2011)
THE PARATHYROID GLANDS: WHAT THE ENDOCRINE SURGEON SHOULD KNOW Indian Rhino Club
Nancy D. Perrier
ENDOCRINE PRACTICE (2011)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
M. Nowicki et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Management of type 2 diabetes: new and future developments in treatment
Abd A. Tahrani et al.
LANCET (2011)
Type 2 diabetes across generations: from pathophysiology to prevention and management
Christopher J. Nolan et al.
LANCET (2011)
PDB45 COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN SPAIN
de Ramirez et al.
VALUE IN HEALTH (2011)
COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
A. Hutchings et al.
VALUE IN HEALTH (2011)
COST-EFFECTIVENESS OF SAXAGLIPTIN TREATMENT IN THREE LATIN AMERICAN COUNTRIES
J. F. Elgart et al.
VALUE IN HEALTH (2011)
Dipeptidylpeptitase-4 Inhibitors (Gliptins) Focus on Drug-Drug Interactions
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2010)
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
Mark Kirby et al.
CLINICAL SCIENCE (2010)
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
A. J. Scheen
DIABETES OBESITY & METABOLISM (2010)
Mortality attributable to diabetes: Estimates for the year 2010
Gojka Roglic et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Global estimates of the prevalence of diabetes for 2010 and 2030
J. E. Shaw et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
Andre J. Scheen et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
Alogliptin A Review of its Use in the Management of Type 2 Diabetes Mellitus
Lesley J. Scott
DRUGS (2010)
Sitagliptin A Review of its Use in the Management of Type 2 Diabetes Mellitus
Sohita Dhillon
DRUGS (2010)
Vildagliptin A Review of its Use in Type 2 Diabetes Mellitus
Gillian M. Keating
DRUGS (2010)
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
B. Goke et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Effect of a High-Fat Meal on the Pharmacokinetics of Saxagliptin in Healthy Subjects
Chirag G. Patel et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors
Priscilla A. Hollander et al.
POSTGRADUATE MEDICINE (2010)
Reaching HbA(1c) Goals with Saxagliptin in Combination with Other Oral Antidiabetic Drugs
James R. LaSalle
POSTGRADUATE MEDICINE (2010)
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
Robert Frederich et al.
POSTGRADUATE MEDICINE (2010)
COST-UTILITY ANALYSIS OF SAXAGLIPTIN AS AN ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES PATIENTS FROM THE BRAZILIAN PRIVATE HEALTH SYSTEM
F. G. Eliaschewitz et al.
VALUE IN HEALTH (2010)
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
Baptist Gallwitz
Diabetes Metabolic Syndrome and Obesity-Targets and Therapy (2010)
Saxagliptin for type 2 diabetes
Antonio R. Chacra
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2010)
Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes
J. Rosenstock et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
Ralph A. DeFronzo et al.
DIABETES CARE (2009)
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
M. Jadzinsky et al.
DIABETES OBESITY & METABOLISM (2009)
Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle
N. Temofonte et al.
DIABETOLOGIA (2009)
Pharmacological Antihyperglycemic Therapy of Type 2 Diabetes mellitus Update of the Evidence-Based Guidelines of the German Diabetes Association
S. Matthaei et al.
DIABETOLOGIE UND STOFFWECHSEL (2009)
STATEMENT BY AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS PANEL ON TYPE 2 DIABETES MELLITUS: AN ALGORITHM FOR GLYCEMIC CONTROL
Helena W. Rodbard et al.
ENDOCRINE PRACTICE (2009)
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
A. R. Chacra et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone
Priscilla Hollander et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2008)
Assessing the cardiovascular safety of diabetes therapies
Allison B. Goldfine
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The role of gut hormones in glucose homeostasis
Daniel J. Drucker
JOURNAL OF CLINICAL INVESTIGATION (2007)
Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster)
P McEwan et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
DJ Augeri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
PM Clarke et al.
DIABETOLOGIA (2004)
Share Paper
